Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection

The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism

Shilpa Medicare aims for US approval of chemo nausea drug

Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections

Alkem launches innovative hair growth support therapy kit

The supplements are made using only vegetarian-sourced ingredients

GSK reports breakthrough results in chronic hepatitis B trials

Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis

The FDA designation follows visual-function results from the Phase 2 ACUITY trial

Leeford Healthcare bets Rs. 200 crore on orthopedic & mobility aids

Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer

Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis